Compare CLPS & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLPS | ESLA |
|---|---|---|
| Founded | 2005 | 2021 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.3M | 32.5M |
| IPO Year | 2017 | 2021 |
| Metric | CLPS | ESLA |
|---|---|---|
| Price | $0.81 | $0.64 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 8.9K | ★ 4.2M |
| Earning Date | 10-16-2026 | 11-24-2026 |
| Dividend Yield | ★ 14.94% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.80 | $0.24 |
| 52 Week High | $1.24 | $2.43 |
| Indicator | CLPS | ESLA |
|---|---|---|
| Relative Strength Index (RSI) | 40.55 | 53.48 |
| Support Level | $0.86 | $0.34 |
| Resistance Level | $0.95 | $0.85 |
| Average True Range (ATR) | 0.07 | 0.15 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 31.58 | 38.63 |
CLPS Inc is information technology, consulting and solutions service provider, focused on delivering services mainly to world-wide institutions, including banking, wealth management, ecommerce, and automotive areas both in China and globally. It has been at the forefront of driving digital transformation and optimizing operational efficiency across industries through innovations in artificial intelligence (AI), cloud computing, and data. It diverse business lines span sectors including fintech, payment and credit services, e-commerce, education and study abroad programs, and world-wide tourism integrated with transportation services. Its segments are IT services and academic education service. Majority of revenue comes from IT services segment. Its products are NiBot RPA, and CAKU.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.